Table of Contents Author Guidelines Submit a Manuscript
Table of Contents Alerts

To receive news and publication updates for Mediators of Inflammation, enter your email address in the box below.

Mediators of Inflammation
Volume 2012 (2012), Article ID 936721, 10 pages
http://dx.doi.org/10.1155/2012/936721
Review Article

Systemic Treatment of Vitreous Inflammation

John B. Christoforidis, Susie Chang, Angela Jiang, Jillian Wang, and Colleen M. Cebulla

Retina Division, Department of Ophthalmology, Wexner Medical Center at The Ohio State University, 915 Olentangy River Road, Suite 5000, Columbus, OH 43212, USA

Received 14 June 2012; Accepted 21 August 2012

Academic Editor: Mario R. Romano

Copyright © 2012 John B. Christoforidis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. S. Foster and A. T. Vitale, Diagnosis and Treatment of Uveitis, vol. 16, W.B. Saunders, Philadelphia, Pa, USA, 2002.
  2. D. A. Jabs and E. K. Akpek, “Immunosuppression for posterior uveitis,” Retina, vol. 25, no. 1, pp. 1–18, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Kovacs, S. Wagley, M. T. Quirk et al., “Pharmacokinetic study of vitreous and serum concentrations of triamcinolone acetonide after posterior sub-tenon's injection,” American Journal of Ophthalmology, vol. 153, no. 5, pp. 939–948, 2012. View at Publisher · View at Google Scholar
  4. D. M. Albert and F. A. Jakobiec, Principles and Practice of Ophthalmology, W.B. Saunders, Philadelphia, Pa, USA, 2nd edition, 2000.
  5. N. A. Sabrosa and C. Pavésio, “Treatment strategies in patients with posterior uveitis,” International Ophthalmology Clinics, vol. 40, no. 2, pp. 153–161, 2000. View at Google Scholar · View at Scopus
  6. K. Durrani, F.R. Zakka, M. Ahmed, M. Memon, S.S. Siddique, and C.S. Foster, “Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease,” Survey of Ophthalmology, vol. 56, no. 6, pp. 474–510, 2011. View at Publisher · View at Google Scholar
  7. A. A. Okada, “Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature,” Ocular Immunology and Inflammation, vol. 13, no. 5, pp. 335–351, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. T. J. Zimmerman, Textbook of Ocular Pharmacology, vol. 29, Lippincott-Raven, Philadelphia, Pa, USA, 1997.
  9. S. Bom, P. Zamiri, and S. Lightman, “Use of methotrexate in the management of sight-threatening uveitis,” Ocular Immunology and Inflammation, vol. 9, no. 1, pp. 35–40, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. F. G. Holz, H. Krastel, A. Breitbart, M. Schwarz-Eywill, A. Pezzutto, and H. E. Völcker, “Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids.,” German Journal of Ophthalmology, vol. 1, no. 3-4, pp. 142–144, 1992. View at Google Scholar · View at Scopus
  11. A. Kaplan-Messas, Y. Barkana, I. Avni, and R. Neumann, “Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis,” Ocular Immunology and Inflammation, vol. 11, no. 2, pp. 131–139, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. S. S. Shah, C. Y. Lowder, M. A. Schmitt, W. S. Wilke, G. S. Kosmorsky, and D. M. Meisler, “Low-dose methotrexate therapy for ocular inflammatory disease,” Ophthalmology, vol. 99, no. 9, pp. 1419–1423, 1992. View at Google Scholar · View at Scopus
  13. S. Gangaputra, C. W. Newcomb, T. L. Liesegang et al., “Methotrexate for ocular inflammatory diseases,” Ophthalmology, vol. 116, no. 11, pp. 2188–e1, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. C. M. Samson, N. Waheed, S. Baltatzis, and C. S. Foster, “Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients,” Ophthalmology, vol. 108, no. 6, pp. 1134–1139, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. M. E. Weinblatt, “Toxicity of low dose methotrexate in rheumatoid arthritis,” Journal of Rheumatology, vol. 12, supplement 12, pp. 35–39, 1985. View at Google Scholar · View at Scopus
  16. D. BenEzra and E. Cohen, “Cataract surgery in children with chronic uveitis,” Ophthalmology, vol. 107, no. 7, pp. 1255–1260, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. F. F. Lee and C. S. Foster, “Pharmacotherapy of uveitis,” Expert Opinion on Pharmacotherapy, vol. 11, no. 7, pp. 1135–1146, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. G. B. Elion, “Pharmacologic and physical agents. Immunosuppressive agents.,” Transplantation Proceedings, vol. 9, no. 1, pp. 975–979, 1977. View at Google Scholar · View at Scopus
  19. G. L. C. Chan, D. M. Canafax, and C. A. Johnson, “The therapeutic use of azathioprine in renal transplantation,” Pharmacotherapy, vol. 7, no. 5, pp. 165–177, 1987. View at Google Scholar · View at Scopus
  20. P. L. Hooper and H. J. Kaplan, “Triple agent immunosuppression in serpiginous choroiditis,” Ophthalmology, vol. 98, no. 6, pp. 944–952, 1991. View at Google Scholar · View at Scopus
  21. S. S. Michel, A. Ekong, S. Baltatzis, and C. S. Foster, “Multifocal choroiditis and panuveitis: immunomodulatory therapy,” Ophthalmology, vol. 109, no. 2, pp. 378–383, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. V. P. J. Saw, J. K. G. Dart, S. Rauz et al., “Immunosuppressive therapy for ocular mucous membrane pemphigoid. Strategies and outcomes,” Ophthalmology, vol. 115, no. 2, pp. 253–e1, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. J. K. Whisnant and J. Pelkey, “Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities,” Annals of the Rheumatic Diseases, vol. 41, supplement 1, pp. 44–47, 1982. View at Google Scholar · View at Scopus
  24. C. S. Foster and A. T. Vitale, “Immunosuppressive chemotherapy,” in Diagnosis and Treatment of Uveitis, C. S. Foster and A. T. Vitale, Eds., W.B. Saunders, Philadelphia, Pa, USA, 2002. View at Google Scholar
  25. D. Vavvas and C. S. Foster, “Immunomodulatory medications in uveitis,” International Ophthalmology Clinics, vol. 44, no. 3, pp. 187–203, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. A. C. Allison and E. M. Eugui, “Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil,” Immunological Reviews, no. 136, pp. 5–28, 1993. View at Google Scholar · View at Scopus
  27. R. Voisard, S. Viola, V. Kaspar et al., “Effects of mycophenolate mofetil on key pattern of coronary restenosis: a cascade of in vitro and ex vivo models,” BMC Cardiovascular Disorders, vol. 5, no. 1, p. 9, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Baltatzis, F. Tufail, E. N. Yu, C. M. Vredeveld, and C. S. Foster, “Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders,” Ophthalmology, vol. 110, no. 5, pp. 1061–1065, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Sobrin, W. Christen, and C. S. Foster, “Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis,” Ophthalmology, vol. 115, no. 8, pp. 1416–e1, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. D. A. Jabs, J. T. Rosenbaum, C. S. Foster et al., “Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel,” American Journal of Ophthalmology, vol. 130, no. 4, pp. 492–513, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. R. I. Fox, M. L. Herrmann, C. G. Frangou et al., “Mechanism of action for leflunomide in rheumatoid arthritis,” Clinical Immunology, vol. 93, no. 3, pp. 198–208, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. H. T. Silva Jr and R. E. Morris, “Leflunomide and malononitriloamides,” Expert Opinion on Investigational Drugs, vol. 6, no. 1, pp. 51–64, 1997. View at Publisher · View at Google Scholar · View at Scopus
  33. Anon, Leflunomide ADIS R&D Insight ADIS International, April 1998.
  34. R. P. Baughman and E. E. Lower, “Leflunomide for chronic sarcoidosis,” Sarcoidosis Vasculitis and Diffuse Lung Diseases, vol. 21, no. 1, pp. 43–48, 2004. View at Google Scholar · View at Scopus
  35. H. M. Roussel, Summary of Product Characteristics for Arava, Hoechst Marion Roussel, Uxbridge, UK, 1999.
  36. S. Cohen, G.W. Cannon, M. Schiff et al., “Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate,” Arthritis and Rheumatism, vol. 44, no. 9, pp. 1984–1992, 2001. View at Publisher · View at Google Scholar
  37. A. S. Fauci, S. M. Wolff, and J. S. Johnson, “Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis.,” New England Journal of Medicine, vol. 285, no. 27, pp. 1493–1496, 1971. View at Google Scholar · View at Scopus
  38. C. E. Buckley III and J. P. Gills Jr, “Cyclophosphamide therapy of Behcet's disease,” Journal of Allergy, vol. 43, no. 5, pp. 273–283, 1969. View at Google Scholar · View at Scopus
  39. C. S. Foster, L. A. Wilson, and M. B. Ekins, “Immunosuppressive therapy for progressive ocular cicatricial pemphigoid,” Ophthalmology, vol. 89, no. 4, pp. 340–353, 1982. View at Google Scholar · View at Scopus
  40. W. M. Fosdick, J. L. Parsons, and D. F. Hill, “Long-term cyclophosphamide therapy in rheumatoid arthritis.,” Arthritis and Rheumatism, vol. 11, no. 2, pp. 151–161, 1968. View at Google Scholar · View at Scopus
  41. R. Brubaker, R. L. Font, and E. M. Shepherd, “Granulomatous sclerouveitis. Regression of ocular lesions with cyclophosphamide and prednisone,” Archives of Ophthalmology, vol. 86, no. 5, pp. 517–524, 1971. View at Google Scholar · View at Scopus
  42. A. S. Fauci, J. L. Doppman, and S. M. Wolff, “Cyclophosphamide-induced remissions in advanced polyarteritis nodosa,” American Journal of Medicine, vol. 64, no. 5, pp. 890–894, 1978. View at Google Scholar · View at Scopus
  43. T. Hoang-Xuan, C. S. Foster, and B. A. Rice, “Scleritis in relapsing polychondritis. Response to therapy,” Ophthalmology, vol. 97, no. 7, pp. 892–898, 1990. View at Google Scholar · View at Scopus
  44. K. Durrani, G. N. Papaliodis, and C. S. Foster, “Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety,” Ophthalmology, vol. 111, no. 5, pp. 960–965, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. B. A. Chabner, P. C. Amrein, B. Druker et al., “Antineoplastic agents,” in Goodman & Gilman's the Pharmacological Basis of Therapeutics, L. S. Goodman, A. Gilman, L. L. Brunton, J. S. Lazo, and K. L. Parker, Eds., pp. 1315–1404, McGraw-Hill, New York, NY, USA, 2006. View at Google Scholar
  46. E. Miserocchi, S. Baltatzis, A. Ekong, M. Roque, and C. S. Foster, “Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts eye and ear infirmary experience,” Ophthalmology, vol. 109, no. 1, pp. 137–142, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. A. B. Mudun, A. Ergen, S. U. Ipcioglu, E. Yarkin Burumcek, Y. Durlu, and M. Okan Arslan, “Short-term chlorambucil for refractory uveitis in Behcet's disease,” Ocular Immunology and Inflammation, vol. 9, no. 4, pp. 219–229, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. G. W. Cannon, C. G. Jackson, and C. O. Samuelson, “Chlorambucil therapy in rheumatoid arthritis: clinical experience in 28 patients and literature review,” Seminars in Arthritis and Rheumatism, vol. 15, no. 2, pp. 106–118, 1985. View at Google Scholar · View at Scopus
  49. K. F. Tabbara, “Chlorambucil in Behcet's disease. A reappraisal,” Ophthalmology, vol. 90, no. 8, pp. 906–908, 1983. View at Google Scholar · View at Scopus
  50. D. A. Gerber, C. A. Bonham, and A. W. Thomson, “Immunosuppressive agents: recent developments in molecular action and clinical application,” Transplantation Proceedings, vol. 30, no. 4, pp. 1573–1579, 1998. View at Publisher · View at Google Scholar · View at Scopus
  51. A. G. Palestine, R. B. Nussenblatt, and M. Gelato, “Therapy for human autoimmune uveitis with low-dose cyclosporine plus bromocriptine,” Transplantation Proceedings, vol. 20, no. 3, supplement 4, pp. 131–135, 1988. View at Google Scholar · View at Scopus
  52. A. T. Vitale, A. Rodriguez, and C. S. Foster, “Low-dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy,” Ophthalmology, vol. 101, no. 5, pp. 822–831, 1994. View at Google Scholar · View at Scopus
  53. J. Liu, J. D. Farmer, W. S. Lane, J. Friedman, I. Weissman, and S. L. Schreiber, “Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes,” Cell, vol. 66, no. 4, pp. 807–815, 1991. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Mochizuki, K. Masuda, T. Sakane et al., “A clinical trial of FK506 in refractory uveitis,” American Journal of Ophthalmology, vol. 115, no. 6, pp. 763–769, 1993. View at Google Scholar · View at Scopus
  55. D. J. Kilmartin, J. V. Forrester, and A. D. Dick, “Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis,” Ocular Immunology and Inflammation, vol. 6, no. 2, pp. 101–109, 1998. View at Publisher · View at Google Scholar · View at Scopus
  56. C. M. L. Sloper, R. J. Powell, and H. S. Dua, “Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine,” Ophthalmology, vol. 106, no. 4, pp. 723–728, 1999. View at Google Scholar · View at Scopus
  57. M. Naesens, D. R. J. Kuypers, and M. Sarwal, “Calcineurin inhibitor nephrotoxicity,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 2, pp. 481–508, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. Y. Miwa, T. Isozaki, K. Wakabayashi et al., “Tacrolimus-induced lung injury in a rheumatoid arthritis patient with interstitial pneumonitis,” Modern Rheumatology, vol. 18, no. 2, pp. 208–211, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. M. M. O'Donnell, J. P. Williams, R. Weinrieb, and L. Denysenko, “Catatonic mutism after liver transplant rapidly reversed with lorazepam,” General Hospital Psychiatry, vol. 29, no. 3, pp. 280–281, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. V. A. Shanmuganathan, E. M. Casely, D. Raj et al., “The efficacy of sirolimus in the treatment of patients with refractory uveitis,” British Journal of Ophthalmology, vol. 89, no. 6, pp. 666–669, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. B. N. Phillips and K. J. Wroblewski, “A retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis,” Journal of Ophthalmic Inflammation and Infection, vol. 1, no. 1, pp. 29–34, 2011. View at Publisher · View at Google Scholar
  62. A. Reiff, “Long-term outcome of etanercept therapy in children with treatment-refractory uveitis,” Arthritis and Rheumatism, vol. 48, no. 7, pp. 2079–2080, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. P. P. Sfikakis, “Behçet's disease: a new target for anti-tumour necrosis factor treatment,” Annals of the Rheumatic Diseases, vol. 61, supplement 2, pp. ii51–ii53, 2002. View at Google Scholar · View at Scopus
  64. L. L. Lim, F. W. Fraunfelder, and J. T. Rosenbaum, “Do tumor necrosis factor inhibitors cause uveitis? A registry-based study,” Arthritis and Rheumatism, vol. 56, no. 10, pp. 3248–3252, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Galor, V. L. Perez, J. P. Hammel, and C. Y. Lowder, “Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation,” Ophthalmology, vol. 113, no. 12, pp. 2317–2323, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. S. B. Desai and D. E. Furst, “Problems encountered during anti-tumour necrosis factor therapy,” Best Practice and Research, vol. 20, no. 4, pp. 757–790, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. N. Scheinfeld, “A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab,” Journal of Dermatological Treatment, vol. 15, no. 5, pp. 280–294, 2004. View at Publisher · View at Google Scholar · View at Scopus
  68. J. Lin, D. Ziring, S. Desai et al., “TNFalpha blockade in human diseases: an overview of efficacy and safety,” Clinical Immunology, vol. 126, no. 1, pp. 13–30, 2008. View at Publisher · View at Google Scholar
  69. L. H. Calabrese, “Molecular differences in anticytokine therapies,” Clinical and Experimental Rheumatology, vol. 21, no. 2, pp. 241–248, 2003. View at Google Scholar · View at Scopus
  70. B. Bodaghi, E. Bui Quoc, B. Wechsler et al., “Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors,” Annals of the Rheumatic Diseases, vol. 64, no. 6, pp. 962–964, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. R. P. Baughman, D. A. Bradley, and E. E. Lower, “Infliximab in chronic ocular inflammation,” International Journal of Clinical Pharmacology and Therapeutics, vol. 43, no. 1, pp. 7–11, 2005. View at Google Scholar · View at Scopus
  72. P. Kahn, M. Weiss, L. F. Imundo, and D. M. Levy, “Favorable response to high-dose infliximab for refractory childhood uveitis,” Ophthalmology, vol. 113, no. 5, pp. 864–e1, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. L. Niccoli, C. Nannini, M. Benucci et al., “Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study,” Rheumatology, vol. 46, no. 7, pp. 1161–1164, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. E. B. Suhler, J. R. Smith, T. R. Giles et al., “Infliximab therapy for refractory uveitis: 2-Year results of a prospective trial,” Archives of Ophthalmology, vol. 127, no. 6, pp. 819–822, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. J. Braun, J. Brandt, J. Listing et al., “Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial,” Arthritis and Rheumatism, vol. 48, no. 8, pp. 2224–2233, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. J. J. Gómez-Reino, L. Carmona, V. Rodríguez Valverde, E. M. Mola, and M. D. Montero, “Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report,” Arthritis and Rheumatism, vol. 48, no. 8, pp. 2122–2127, 2003. View at Publisher · View at Google Scholar · View at Scopus
  77. Z. Kaymakcalan, P. Sakorafas, S. Bose et al., “Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor,” Clinical Immunology, vol. 131, no. 2, pp. 308–316, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. B. Mushtaq, T. Saeed, R. D. Situnayake, and P. I. Murray, “Adalimumab for sight-threatening uveitis in Behçet's disease,” Eye, vol. 21, no. 6, pp. 824–825, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Diaz-Llopis, S. García-Delpech, D. Salom et al., “Adalimumab therapy for refractory uveitis: a pilot study,” Journal of Ocular Pharmacology and Therapeutics, vol. 24, no. 3, pp. 351–361, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. J. P. Restrepo and M. P. Molina, “Successful treatment of severe nodular scleritis with adalimumab,” Clinical Rheumatology, vol. 29, no. 5, pp. 559–561, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. L. B. Vazquez-Cobian, T. Flynn, and T. J. A. Lehman, “Adalimumab therapy for childhood uveitis,” Journal of Pediatrics, vol. 149, no. 4, pp. 572–575, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. P. Tynjäaldie;, K. Kotaniemi, P. Lindahl et al., “Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis,” Rheumatology, vol. 47, no. 3, pp. 339–344, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. M. Rudwaleit, E. Rødevand, P. Holck et al., “Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study,” Annals of the Rheumatic Diseases, vol. 68, no. 5, pp. 696–701, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. J. A. Singh, G. A. Wells, R. Christensen et al., “Adverse effects of biologics: a network meta-analysis and Cochrane overview,” Cochrane Database of Systematic Reviews, vol. 2, p. CD008794, 2011. View at Google Scholar · View at Scopus
  85. A. Alonso-Ruiz, J. I. Pijoan, E. Ansuategui, A. Urkaregi, M. Calabozo, and A. Quintana, “Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety,” BMC Musculoskeletal Disorders, vol. 9, p. 52, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. H. Yang, J. Wang, J. Du et al., “Structural basis of immunosuppression by the therapeutic antibody daclizumab,” Cell Research, vol. 20, no. 12, pp. 1361–1371, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. L. Sobrin, J. J. Huang, W. Christen, C. Kafkala, P. Choopong, and C. S. Foster, “Daclizumab for treatment of birdshot chorioretinopathy,” Archives of Ophthalmology, vol. 126, no. 2, pp. 186–191, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. H. N. Sen, G. Levy-Clarke, L. J. Faia et al., “High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis,” American Journal of Ophthalmology, vol. 148, no. 5, pp. 696–e1, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. M. Gallagher, K. Quinones, R. A. Cervantes-Castañeda, T. Yilmaz, and C. S. Foster, “Biological response modifier therapy for refractory childhood uveitis,” British Journal of Ophthalmology, vol. 91, no. 10, pp. 1341–1344, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. P. Bhat, R. A. Castañeda-Cervantes, P. P. Doctor, and C. S. Foster, “Intravenous daclizumab for recalcitrant ocular inflammatory disease,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 247, no. 5, pp. 687–692, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. M. A. Rojas, N. G. Carlson, T. L. Miller, and J. W. Rose, “Long-term daclizumab therapy in relapsing-remitting multiple sclerosis,” Therapeutic Advances in Neurological Disorders, vol. 2, no. 5, pp. 291–297, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. L. Lim, E. B. Suhler, and J. R. Smith, “Biologic therapies for inflammatory eye disease,” Clinical and Experimental Ophthalmology, vol. 34, no. 4, pp. 365–374, 2006. View at Publisher · View at Google Scholar · View at Scopus
  93. F. Davatchi, H. Shams, M. Rezaipoor et al., “Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study),” International Journal of Rheumatic Diseases, vol. 13, no. 3, pp. 246–252, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. S. R. J. Taylor, A. D. Salama, L. Joshi, C. D. Pusey, and S. L. Lightman, “Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis,” Arthritis and Rheumatism, vol. 60, no. 5, pp. 1540–1547, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. C. S. Foster, P. Y. Chang, and A. R. Ahmed, “Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid. A preliminary report,” Ophthalmology, vol. 117, no. 5, pp. 861–869, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. A. Bermudez, F. Marco, E. Conde, E. Mazo, M. Recio, and A. Zubizarreta, “Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma,” Haematologica, vol. 85, no. 8, pp. 894–895, 2000. View at Google Scholar · View at Scopus
  97. P. Quartier, O. Tournilhac, C. Archimbaud et al., “Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment.,” Clinical Infectious Diseases, vol. 36, no. 3, pp. e47–49, 2003. View at Google Scholar · View at Scopus
  98. Genentech, Products-Product Information-Immunology-Rituxan RA Full Prescribing Information, 2007-12-03.
  99. G. Jones, A. Sebba, J. Gu et al., “Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study,” Annals of the Rheumatic Diseases, vol. 69, no. 1, pp. 88–96, 2010. View at Publisher · View at Google Scholar · View at Scopus
  100. V. L. Perez, G. N. Papaliodis, D. Chu, F. Anzaar, W. Christen, and C. S. Foster, “Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies,” Ocular Immunology and Inflammation, vol. 12, no. 3, pp. 193–201, 2004. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Muselier, P. Bielefeld, S. Bidot, J. Vinit, J.-F. Besancenot, and A. Bron, “Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis,” Ocular Immunology and Inflammation, vol. 19, no. 5, pp. 382–383, 2011. View at Publisher · View at Google Scholar
  102. V. Dinnendahl and U. Fricke, Arzneistoff-Profile, vol. 4, Govi Pharmazeutischer Verlag, Eschborn, Germany, 32 edition, 2010.
  103. V. Oldfield, S. Dhillon, and G. L. Plosker, “Tocilizumab a review of its use in the management of rheumatoid arthritis,” Drugs, vol. 69, no. 5, pp. 609–632, 2009. View at Publisher · View at Google Scholar · View at Scopus
  104. F. Hayden, “Antiviral agents (non-retroviral),” in Goodman & Gilman's the Pharmacological Basis of Therapeutics, L. S. Goodman, A. Gilman, L. L. Brunton, J. S. Lazo, and K. L. Parker, Eds., pp. 1243–1272, McGraw-Hill, New York, NY, USA, 2006. View at Google Scholar
  105. S. Mocellin, S. Pasquali, C. R. Rossi, and D. Nitti, “Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis,” Journal of the National Cancer Institute, vol. 102, no. 7, pp. 493–501, 2010. View at Publisher · View at Google Scholar · View at Scopus
  106. E. Alpsoy, C. Durusoy, E. Yilmaz et al., “Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study,” Archives of Dermatology, vol. 138, no. 4, pp. 467–471, 2002. View at Google Scholar · View at Scopus
  107. I. Kotter, R. Vonthein, M. Zierhut et al., “Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial,” Seminars in Arthritis and Rheumatism, vol. 33, no. 5, pp. 311–319, 2004. View at Publisher · View at Google Scholar
  108. F. Mackensen, R. Max, and M. D. Becker, “Interferons and their potential in the treatment of ocular inflammation,” Clinical Ophthalmology, vol. 3, no. 1, pp. 559–566, 2009. View at Google Scholar · View at Scopus
  109. M. D. Becker, A. Heiligenhaus, T. Hudde et al., “Interferon as a treatment for uveitis associated with multiple sclerosis,” British Journal of Ophthalmology, vol. 89, no. 10, pp. 1254–1257, 2005. View at Publisher · View at Google Scholar · View at Scopus
  110. C. M. E. Deuter, M. Zierhut, A. Möhle, R. Vonthein, N. Stübiger, and I. Kötter, “Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease,” Arthritis and Rheumatism, vol. 62, no. 9, pp. 2796–2805, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. I. Kotter, I. Günaydin, M. Zierhut, and N. Stübiger, “The use of interferon alpha in Behcet disease: review of the literature,” Seminars in Arthritis and Rheumatism, vol. 33, no. 5, pp. 320–335, 2004. View at Publisher · View at Google Scholar